公开(公告)号：US11339367B2

公开(公告)日：2022-05-24

申请号：US15094077

申请日：2016-04-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Christiane Gerke ,  Francesco Berlanda Scorza ,  Allan Saul ,  Luana Maggiore

IPC: C12N1/20 ,  C07K14/25 ,  A61K39/00 ,  A61K35/12

Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.

公开(公告)号：US20240000958A1

公开(公告)日：2024-01-04

申请号：US18252783

申请日：2021-11-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Francesca Micoli ,  Roberta Di Benedetto ,  Allan Saul

IPC: A61K47/64 ,  A61K39/09 ,  A61P31/04

CPC classification number: A61K47/646 ,  A61K39/092 ,  A61P31/04 ,  A61K2039/6037

Abstract: The present invention is directed to a polysaccharide conjugate comprising or consisting of a one or more polysaccharide conjugated to a carrier polypeptide, wherein the carrier polypeptide is selected from the group consisting of (a) a Streptococcus pyogenes SpyAD (Spy0269, GAS40), a Streptococcus pyogenes SpyCEP (Spy0416, GAS57), or Streptococcus pyogenes SLO (Spy0167, GAS25); (b) CRM197; or (c) a variant, fragment and/or fusion of (a) or (b), improved conjugation methods, and uses of said conjugates for preventing or treating disease.